Brainstorm Cell Therapeutics (BCLI) Misses Q3 EPS by 35c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.53), $0.35 worse than the analyst estimate of ($0.18).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• PennyMac Mortgage Investment Trust (PMT) PT Lowered to $10 by UBS on Lower MSR Earnings
• Ross Stores (ROST) Tops Q2 EPS by 72c, Beats on Revenue